Xenoantigen-containing lipopeptide vaccines

Description:

Project ID:  D2017-06

 

Background

Results from protein conjugate vaccines have restrictions due to the innate immunogenicity of carrier proteins, which can suppress the response against associated carbohydrate antigen. Thus, the development of fully synthetic carbohydrate vaccines has been under intense investigation in the last decade in immunotherapy. A typical fully synthetic carbohydrate vaccine includes a carbohydrate antigen, T-helper cell epitope, and an immuno-adjuvant to boost the immune response. Tumor-associated carbohydrate antigens (TACAs) found on the outer cell membrane of tumor epithelial cells are promising targets in cancer immunotherapy. Although TACAs are promising targets, carbohydrate antigens are weak immunogens and give a T-cell-independent immune response when used alone. There is, therefore, a need for new vaccine compositions.

 

Invention Description

Researchers at The University of Toledo have developed a vaccine composed of lipidated peptide or glycopeptide antigen that optionally incorporates a xenoantigen. The compositions of the vaccine are more readily assembled than known vaccine components. Furthermore, covalent combination of a lipid antigen and a xenoantigen ensures colocalization of all components.   

 

Applications

•       The invention can be applied to the development of anti-tumor vaccines

 

Advantages

•       The compositions of the vaccine are more readily assembled than known vaccine compositions, incorporating a xenoantigen as part of a second molecule or component

•       Covalent combination of a lipid antigen and xenoantigen ensures colocalization of all components

•       Endogenous natural antibodies against xenoantigens can be used to improve uptake of antigens by antigen presenting cells

 

IP Status:       Patent Pending

 

Publications:       Karmakar P, et al., Synthesis of a liposomal MUC1 glycopeptide-based immunotherapeutic and evaluation of the effect of I-Rhamnose targeting on cellular immune responses. Bioconjugate Chemistry, 2016, 110-120

 

Patent Information:
For Information, Contact:
Kwaku Opoku
Licensing Associate
The University of Toledo
419-530-6231
kwaku.opoku@utoledo.edu
Inventors:
Steven Sucheck
Katherine Wall
Anthony Quinn
Marcia McInerney
Abhishek Vartak
Keywords:
Antigen
Cancer
Carbohydrate
Immunotherapy
Lipopeptide
TACA
Tumor
Vaccine
Xenoantigen